** Shares of Compass Therapeutics CMPX.O down 5.3% post-market to $3.00 after equity raise news

** Boston, Massachusetts-based oncology-focused biopharma launches offering of stock and pre-funded warrants; deal size not disclosed

** Co intends to use net proceeds to conduct initial preparations for commercial readiness, to fund R&D, clinical development of its product candidates, among other purposes

** Jefferies, Piper Sandler and Guggenheim are joint active bookrunners for the offering

** Co has ~138.3 mln shares outstanding for ~$440 mln market cap, per LSEG data

** CMPX shares on Tues finished down 5.1% at $3.17

** Stock gained ~24% on Mon after co reported Q2 results and provided data on its pipeline

** Avg rating among 10 analysts is "strongbuy" and median PT is $10.50 - LSEG

** Shares ended 2024 at $1.45

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))